Potential prognostic, diagnostic and therapeutic markers for human gastric cancer

doi:10.3748/wjg.v20.i38.13791

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 38

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7044)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

552

WORD

360

HTML

4039

Tables (1-2)

163

Sum=5114

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

934

Download

996

Sum=1930

Oct 14, 2014 (publication date) through Aug 3, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 14, 2014; 20(38): 13791-13803
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13791

Table 1 Serum-based tumor markers in gastric cancer

Biological category	Biomarker (Gene name)	Cutoff level /Expression levels in human GC serum	Clinical significance	Associated tumor types	Ref.
Oncofetal antigen	CEA	5 μg/L	Prognosis	Gastrointestinal cancer	[24,25]
			GC progression monitoring	Cervix cancer
				Lung cancer
				Ovary cancer
				Breast cancer
				Urinary tract cancer
Glycoprotein antigen	CA19.9	37 kU/L	Prognosis	Mainly pancreatic cancer	[26]
			GC progression	but also colorectal cancer
			monitoring	other types of gastrointestinal cancer
	CA72.4	6 kU/L	Prognosis	Ovary cancer	[27]
			GC progression	Breast cancer
			monitoring	Colon cancer
				Pancreatic cancer
Cytokeratins	Cyfra21.1	Variable	Prognosis	Many types of carcinoma	[29]
	Cyfra21.1	Variable	Prognosis	Some types of sarcoma	[29]
	TPA	Variable	Prognosis	Carcinoma	[30]
	TPS	Variable	Prognosis	Adult epithelial tumours	[30]
Hormone	Β subunit of hCG	4 μg/L	Prognosis	Seminoma	[31]
				Choriocarcinoma
				Germ cell tumors
				Choriocarcinoma
				Islet cell tumor
				Testicular cancer
Cell proliferation	Reg IV	Overexpression	Prognosis	Gastrointestinal malignancies	[33,34]
Cell proliferation	Granulin	Overexpression	Prognosis	Gastrointestinal malignancies	[35,36]
Signaling protein	14-3-3 protein	Downexpression	Prognosis	Epithelial cancer	[40-42]
				Lung cancer
				Breast cancer
				Bladder cancer
				Liver cancer
				Oral cancer
				Head-and-neck squamous cell cancer
	DKK-1	Overexpression	Prognosis	Prostate cancer	[43-49]
				Breast cancer
				Colon cancer
				Esophageal cancer
				Lung cancer
				Multiple myeloma (MM)
Inflammatory	SAA	Overexpression	Prognosis	Lung cancer	[50,52,53]
				Kidney cancer
				Colon cancer
				Prostate cancer
				Liver cancer
Cell apoptosis	MG7-Ag	Overexpression	Prognosis	Gastrointestinal cancer	[55,56]
Enzyme	PG	Overexpression	Prognosis	Gastrointestinal cancer	[57]

CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; Cyfra21.1: Cytokeratin subunit 19 fragment; TPA: Tissue polypeptide antigen; TPS: Tissue polypeptide-specific antigen; β-hCG: β-subunit of human chorionic gonadotropin; Reg IV: Regenerating gene IV; Dkk-1: Dickkopf-1; SAA: Serum Amyloid A; MG7-Ag: Gastric cancer associated antigen; PG: Pepsinogens.

Citation: Tsai MM, Wang CS, Tsai CY, Chi HC, Tseng YH, Lin KH. Potential prognostic, diagnostic and therapeutic markers for human gastric cancer. World J Gastroenterol 2014; 20(38): 13791-13803
URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13791.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13791